CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 6,000 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Age at least 18 years
  • ✓Pathologically confirmed solid tumor cancer
  • ✓Currently receiving immune checkpoint inhibitor treatment
  • ✓Able to provide informed consent
Key exclusion· 3
  • ✕Age under 18 years
  • ✕Hematological malignancies or solid benign tumors
  • ✕Mental disorders, drug abuse, or social conditions affecting compliance

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04766515
NCT04766515N/ARecruitingUpdate OverdueCompletion was 34mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Multicenter Observational Prospective Study of Immune Checkpoint Inhibitors in Patients With Solid Neoplasms

Fudan University·observational·Posted Feb 23, 2021·Updated Jun 30, 2026

In Brief

An observational study for Cancer. Currently recruiting, targeting 6,000 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesChina
Collaborators--

Timeline

N/ARecruiting
2021202220232024202520262027
First PostedFeb 23, 2021
Enrollment StartSep 1, 2020
Primary CompletionAug 31, 2023
Study CompletionAug 30, 2027
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 5.4 years ago